Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
Date:2/14/2008

683,437

Retained earnings 9,323,261

Accumulated other comprehensive income 1,008,074

Total Stockholders' Equity 15,725,280

Total Liabilities and Stockholders' Equity $18,887,829

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

Six Months Ended Three Months Ended

December 31, December 31,

2007 2006 2007 2006

SALES $14,918,692 $8,210,022 $7,749,199 $4,344,846

COST OF GOODS SOLD 8,861,258 5,091,764 4,567,429 2,702,593

GROSS PROFIT 6,057,434 3,118,258 3,181,770 1,642,253

EXPENSES

Selling, general and

administrative 2,200,541 801,776 1,172,062 457,519

Research and

development 61,558 13,380 34,106 6,269

Total Expenses 2,262,099 815,156 1,206,168 463,788

INCOME FROM OPERATIONS 3,795,335 2,303,102 1,975,602 1,178,466

OTHER INCOME (EXPENSES)

Other income -- 1,432 --

Interest expense (66,362) (71,745) (31,659) (36,604)

Total Other Income

(Expenses) (66,362) (70,313) (31,659) (36,604)

INCOME BEFORE PROVISION FOR

INCOME TAX 3,728,973 2,232,789 1,943,943 1,141,862

PROVISION FOR INCOME TAX 556,646 310,936 291,572 155,545

NET INCOME 3,172,327 1,921,853 1,652,371 986,317

OTHER COMPREHENSIVE INCOME

Foreign currency

translation ad
'/>"/>

SOURCE Tianyin Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email: